Huntington National Bank Has $1.12 Million Stock Holdings in Humana Inc. $HUM

Huntington National Bank cut its holdings in Humana Inc. (NYSE:HUM) by 9.8% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 4,571 shares of the insurance provider’s stock after selling 495 shares during the quarter. Huntington National Bank’s holdings in Humana were worth $1,118,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Corton Capital Inc. acquired a new stake in shares of Humana in the second quarter valued at $356,000. Bank of Montreal Can increased its stake in shares of Humana by 4.4% in the second quarter. Bank of Montreal Can now owns 149,773 shares of the insurance provider’s stock valued at $36,617,000 after buying an additional 6,349 shares in the last quarter. Burney Co. increased its stake in shares of Humana by 366.0% in the second quarter. Burney Co. now owns 12,730 shares of the insurance provider’s stock valued at $3,112,000 after buying an additional 9,998 shares in the last quarter. South Dakota Investment Council increased its stake in shares of Humana by 5.9% in the second quarter. South Dakota Investment Council now owns 165,254 shares of the insurance provider’s stock valued at $40,401,000 after buying an additional 9,224 shares in the last quarter. Finally, State of Michigan Retirement System increased its stake in shares of Humana by 4.0% in the second quarter. State of Michigan Retirement System now owns 34,025 shares of the insurance provider’s stock valued at $8,318,000 after buying an additional 1,300 shares in the last quarter. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Humana Trading Down 5.8%

NYSE:HUM opened at $265.48 on Thursday. Humana Inc. has a fifty-two week low of $206.87 and a fifty-two week high of $315.35. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.95 and a quick ratio of 1.95. The stock has a market capitalization of $31.93 billion, a PE ratio of 20.37, a price-to-earnings-growth ratio of 1.71 and a beta of 0.42. The business’s 50-day simple moving average is $280.01 and its 200-day simple moving average is $258.90.

Humana (NYSE:HUM) last released its quarterly earnings data on Wednesday, November 5th. The insurance provider reported $3.24 earnings per share for the quarter, beating the consensus estimate of $2.95 by $0.29. Humana had a return on equity of 13.67% and a net margin of 1.28%.The business had revenue of $32.65 billion for the quarter, compared to analysts’ expectations of $31.99 billion. During the same quarter in the previous year, the business posted $4.16 EPS. Humana’s revenue for the quarter was up 11.1% on a year-over-year basis. Sell-side analysts expect that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 30th. Stockholders of record on Friday, December 26th will be issued a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a dividend yield of 1.3%. The ex-dividend date is Friday, December 26th. Humana’s payout ratio is 27.17%.

Analyst Ratings Changes

A number of brokerages recently commented on HUM. Royal Bank Of Canada lifted their price objective on Humana from $283.00 to $322.00 and gave the stock an “outperform” rating in a research report on Thursday, August 21st. Wall Street Zen lowered Humana from a “buy” rating to a “hold” rating in a research report on Saturday, August 2nd. The Goldman Sachs Group began coverage on Humana in a research report on Tuesday, October 14th. They issued a “sell” rating and a $235.00 price objective for the company. Guggenheim reiterated a “buy” rating on shares of Humana in a research report on Friday, October 3rd. Finally, Wolfe Research lifted their price objective on Humana from $283.00 to $313.00 and gave the stock an “outperform” rating in a research report on Monday, October 6th. Eight research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $299.22.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.